Magnetised thermo responsive lipid vehicles for targeted and controlled lung drug delivery

Pharmaceutical Research

Volumn 29, Issue 9, 2012, Pages 2456-2467

  Upadhyay, Dhrumil ^a   Scalia, Santo ^b   Vogel, Robert ^d   Wheate, Nial ^c   Salama, Rania O ^a,e   Young, Paul M ^a   Traini, Daniela ^a   Chrzanowski, Wojciech ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Controlled drug delivery; Inhalation; Iron oxide; Lipid; Magneto responsive; Thermo responsive; Triggered drug release

Indexed keywords

BUDESONIDE; DRUG VEHICLE; LIPID DRUG VEHICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

AEROSOL; ARTICLE; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DIFFUSION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRY POWDER; EMULSION; HEAT SENSITIVITY; HIGH TEMPERATURE PROCEDURES; IN VITRO STUDY; LIPOSOMAL DELIVERY; MAGNETIC FIELD; PARTICLE SIZE; PERFORMANCE MEASUREMENT SYSTEM; POWDER INHALER; PRIORITY JOURNAL;

AEROSOLS; CALORIMETRY, DIFFERENTIAL SCANNING; LIPIDS; LUNG; MAGNETICS; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; PHARMACEUTICAL VEHICLES; SOLUBILITY; SPECTRUM ANALYSIS, RAMAN; X-RAY DIFFRACTION;

EID: 84866735125     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0774-9     Document Type: Article

References (52)

1. Lubbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting. J Surg Res. 2001;95(2):200-6.
2. Organization, W.H., Cancer, in Fact sheet N297. 2009.
3. Silvestri GA, Alberg AJ, Ravenel J. The changing epidemiology of lung cancer with a focus on screening. Br Med J. 2009;339 (b3053):451-4.
4. Limited TG, Therapeutic Guidelines: Respiratory. Therapeutic Guidelines, ed. T.G. Limited. Vol. 3. 2005, Melbourne. 210.
5. Martin AR, Finlay WH. Alignment of magnetite-loaded high aspect ratio aerosol drug particles with magnetic fields. Aerosol Sci Technol. 2008;42:295-8.
6. Martin AR, Finlay WH. Enhanced deposition of high aspect ratio aerosols in small airway bifurcations usingmagnetic field alignment. J Aerosol Sci. 2008;39(8):295.
7. Gupta AK, et al. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26 (18):3995-4021.
8. Douziech-Eyrolles L, et al. Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles. Int J Nanomedicine. 2007;2(4):541-50.
9. Amirfazli A, Amirfazli A. Nanomedicine: Magnetic nanoparticles hit the target. Nat Nanotechnol. 2007;2(8):467-8.
10. Veiseh O, et al. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010;62(3):284-304.
11. Cunningham CH, et al. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn Reson Med. 2005;53(5):999-1005.
12. Anderson SA, et al. Magnetic resonance contrast enhancement neovasculature with a(v)β3-targeted nanoparticles. Magn Reson Med. 2000;44(3):433-9.
13. Polyak B, Friedman G. Magnetic targeting for site-specific drug delivery: Applications and clinical potential. Expert Opin Drug Deliv. 2009;6(1):53-70.
14. Jalilian AR, et al. Preparation and biological evaluation of [67Ga]-labeled-superparamagnetic nanoparticles in normal rats. Radiochim Acta. 2009;97(1):51-6.
15. Talelli M, et al. Superparamagnetic iron oxide nanoparticles encapsulated in biodegradable thermosensitive polymeric micelles: Toward a targeted nanomedicine suitable for image-guided drug delivery. Langmuir. 2009;25(4):2060-7.
16. Shubayev VI, Pisanic TR, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev. 2009;61(6):467-77.
17. Jain TK, et al. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats.Mol Pharm. 2008;5(2):316-27.
18. Soenen SJ, et al. Cellular toxicity of inorganic nanoparticles: Common aspects and guidelines for improved nanotoxicity evaluation. Nano Today. 2011;6(5):446-65.
19. Neuberger T, et al. Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J Magn Magn Mater. 2005;293(1):483-96.
20. Kettering M, et al. Characterization of iron oxide nanoparticles adsorbed with cisplatin for biomedical applications. Phys Med Biol. 2009;54(17):5109-21.
21. Dames P, et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol. 2007;2(8):495-9.
22. Son Y-J, McConville JT. Advancements in dry powder delivery to the lung. Drug Dev Ind Pharm. 2008;34(9):948-59.
23. Reddy LH, et al. Tamoxifen citrate loaded solid lipid nanoparticles (SLN): Preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm Dev Technol. 2006;11 (2):167-77.
24. Mezzena M, et al. Solid lipid budesonide microparticles for controlled release inhalation therapy. AAPS J. 2009;11(4):771-8.
25. Weyhers H, et al. Solid lipid nanoparticles (SLN)-effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie. 2006;61(6):539-44.
26. Sanna V, et al. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS PharmSciTech. 2004;5(2):e27.
27. Patton JS, Byron PR. Inhaling medicines: Delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67-74.
28. Salama RO, et al. Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm. 2008;70(1):145-52.
29. Salama RO, et al. Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm. 2008;70(1):145-52.
30. Young PM, et al. Recent advances in understanding the influence of composite-formulation properties on the performance of dry powder inhalers. Physica B. 2007;394(2):315-9.
31. Martonen TB, et al. Issues in drug delivery: Concepts and practice. Respir Care. 2005;50(9):25.
32. Bhavsar MD, Tiwari SB, Amiji MM. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release. 2006;110(2):422-30.
33. Heslinga MJ, Mastria EM, Eniola-Adefeso O. Fabrication of biodegradable spheroidal microparticles for drug delivery applications. J Control Release. 2009;138(3):235-42.
34. Sturesson C, et al. Encapsulation of rotavirus into poly(lactide- coglycolide) microspheres. J Control Release. 1999;59(3):377-89.
35. Sowerby SJ, Broom MF, Petersen GB. Dynamically resizable nanometre-scale apertures for molecular sensing. Sensors Actuators B Chem. 2007;123(1):325-30.
36. Willmott GR, et al. Use of tunable nanopore blockade rates to investigate colloidal dispersions. J Phys Condens Matter. 2010;22 (45):454116.
37. Roberts GS, et al. Tunable nano/micropores for particle detection and discrimination: Scanning ion occlusion spectroscopy. Small. 2010;6(23):2653-8.
38. Vogel R, et al. Quantitative sizing of nano/microparticles with a tunable elastomeric pore sensor. Anal Chem. 2011;83(9):3499-506.
39. Ali HRH, et al. Vibrational spectroscopic study of budesonide. J Raman Spectrosc. 2007;38(7):903-8.
40. Jores K, et al. Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy. Pharm Res. 2005;22(11):1887-97.
41. Hamdani J, et al. Physical and thermal characterisation of Precirol and Compritol as lipophilic glycerides used for the preparation of controlled-release matrix pellets. Int J Pharm. 2003;260(1):47-57.
42. Renishaw P. How Renishaw's inVia Raman system provides high spectral resolution from a 250 mm focal length spectrometer. Technology note from the Spectroscopy Products Division, 2005(1).
43. Gupta M, Bhargava HN. Development and validation of a highperformance liquid chromatographic method for the analysis of budesonide. J Pharm Biomed Anal. 2006;40(2):423-8.
44. Poklar N, et al. Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex. Proc Natl Acad Sci. 1996;93(15):7606-11.
45. Montaseri H, et al. The effect of temperature, ph, and different solubilizing agents on stability of taxol. Iranian J Pharm Sci. 2004;1(1):8.
46. Jordan A. Hyperthermia classic commentary: Inductive heating of ferrimagnetic particles and magnetic fluids: Physical evaluation of their potential for hyperthermia by Andreas Jordan et al., International Journal of Hyperthermia, 1993;9:51-68. Vol. 25. 2009. 512-6.
47. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010;62(3):284-304.
48. Veiseh O, et al. Cancer cell invasion: Treatment and monitoring opportunities in nanomedicine. Adv Drug Deliv Rev. 2011;63 (8):582-96.
49. Wauthoz N, et al. In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. Eur J Pharm Sci. 2010;39 (5):402-11.
50. Shoaib MH, et al. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC. Pak J Pharm Sci. 2006;19(2):119-24.
51. Joshi MR, Misra A. Liposomal budesonide for dry powder inhaler: Preparation and stabilization. AAPS PharmSciTech. 2001;2(4):25.
52. Hoe S, Young PM, Traini D. A review of electrostatic measurement techniques for aerosol drug delivery to the lung: Implications in aerosol particle deposition. J Adhes Sci Technol. 2011;25(4-5):385-405.